Literature DB >> 12898793

Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone.

S Y Kalinchenko1, G I Kozlov, N P Gontcharov, G V Katsiya.   

Abstract

AIMS: To evaluate the cause of failure of sildenafil citrate (Viagra) to restore erections in patients with organic erectile dysfunction (ED) associated with type II diabetes mellitus (DM) and receiving oral antidiabetic drugs.
METHODS: Diabetic ED patients (n = 120), aged 43-74 years, failing to respond at least three times to 100 mg Viagra were evaluated. After at least 2 weeks' treatment with oral testosterone undecanoate (Andriol), 100 mg Viagra was used before coitus. ED was assessed with the International Index of Erectile Function (IIEF). Serum total testosterone, prolactin, thyroid stimulating hormone, lipid profile and prostate-specific antigen (PSA) were determined by standard methods and prostate volume by digital rectal examination. Age-matched diabetic ED patients (n = 100) served as controls for baseline values.
RESULTS: Viagra non-responders had, at baseline, significantly lower testosterone and more depressed libido than controls. Andriol restored testosterone to normal levels and increased libido. In 84/120 (70%) Viagra non-responders, combined therapy with Andriol induced satisfactory erections, a significant increase in IIEF scale (question (Q) 3 from 2.0 +/- 0.2 to 3.7 +/- 0.3, Q4 from 1.9 +/- 0.1 to 3.4 +/- 0.2, Q12 from 1.0 +/- 0.1 to 4.2 +/- 0.4) and increased sexual contacts from 0.5 to 3-4 per month. No adverse events were noted, and PSA levels remained below 4 ng/ml.
CONCLUSION: Decreased testosterone levels in patients with ED and type II DM receiving oral antidiabetic against may be responsible for failure to respond to sildenafil citrate therapy. Combination with oral testosterone undecanoate restores sexual function in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898793

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  25 in total

1.  Men's aging and sexual disorders: an update on diagnosis and treatment.

Authors:  Alvaro Morales
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 2.  Treating erectile dysfunction when PDE5 inhibitors fail.

Authors:  Chelsea N McMahon; Christopher J Smith; Ridwan Shabsigh
Journal:  BMJ       Date:  2006-03-11

Review 3.  Androgens are fundamental in the maintenance of male sexual health.

Authors:  Alvaro Morales
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

4.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

Review 5.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Management of erectile dysfunction in diabetes: an update for 2008.

Authors:  David Price; Geoffrey Hackett
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

Review 7.  Erectile dysfunction: management update.

Authors:  Luke Fazio; Gerald Brock
Journal:  CMAJ       Date:  2004-04-27       Impact factor: 8.262

Review 8.  Risks and benefits of testosterone therapy in older men.

Authors:  Matthew Spitzer; Grace Huang; Shehzad Basaria; Thomas G Travison; Shalender Bhasin
Journal:  Nat Rev Endocrinol       Date:  2013-04-16       Impact factor: 43.330

Review 9.  The many faces of testosterone.

Authors:  Jerald Bain
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.